• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tourmaline Bio, Inc. - Common Stock (NQ: TRML )

26.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 26.90
Bid (Size) 26.70 (3)
Ask (Size) 42.77 (1)
Prev. Close 26.90
Today's Range 26.90 - 26.90
52wk Range 12.12 - 48.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tourmaline Bio to Present at Upcoming Investor Conferences
October 31, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
October 15, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire

Performance

YTD
+1.51%
+1.51%
1 Month
+0.90%
+0.90%
3 Month
+83.62%
+83.62%
6 Month
+73.21%
+73.21%
1 Year
+69.50%
+69.50%

More News

Read More
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
October 11, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
March 19, 2024
Via InvestorPlace
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
October 08, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at Upcoming Investor Conferences
September 03, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
August 08, 2024
Via InvestorPlace
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
August 02, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
June 27, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
May 13, 2024
Via InvestorPlace
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From Avalo Therapeutics
Via GlobeNewswire
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 21, 2024
Via Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
March 21, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 21, 2024
Via Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 21, 2024
Via Benzinga
Topics Stocks
Exposures US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 19, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
January 29, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
January 25, 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap